SCHEMBL3242255

SCHEMBL3242255

CCOC(=O)c1cc(F)c(C(=O)O)cc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
HSD17B10 Q99714 6/20 0.49
GAA P10253 4/20 0.44
MAPK1 P28482 1/20 0.44
TSHR P16473 2/20 0.43
MAPT P10636 4/20 0.43
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
HPGD P15428 3/20 0.43
ALOX15 P16050 2/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 6/20 0.41
NPC1 O15118 3/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41
CA14 Q9ULX7 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7471868 0.85 ALDH1A1 (0.63) ALDH1A1HSD17B10GAAMAPK1TSHR
SCHEMBL1966248 0.83 ALDH1A1 (0.54) ALDH1A1HSD17B10GAAMAPK1TSHR
SCHEMBL2596428 0.82 ALDH1A1 (0.53) ALDH1A1HSD17B10GAAMAPK1TSHR
SCHEMBL9573792 0.81 ALDH1A1 (0.49) ALDH1A1HSD17B10GAAMAPK1TSHR
SCHEMBL1567668 0.81 HSD17B10 (0.51) ALDH1A1HSD17B10GAAMAPK1TSHR
SCHEMBL17930512 0.81 ALDH1A1 (0.51) ALDH1A1HSD17B10GAAMAPK1TSHR
SCHEMBL12685916 0.78 ALDH1A1 (0.49) ALDH1A1HSD17B10GAAMAPK1TSHR
SCHEMBL9710977 0.78 ALDH1A1 (0.49) ALDH1A1HSD17B10GAAMAPK1TSHR
SCHEMBL21154860 0.78 TSHR (0.51) ALDH1A1HSD17B10TSHRMAPTSMN1; SMN2
SCHEMBL364335 0.78 TSHR (0.53) ALDH1A1HSD17B10GAAMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458392-B9 ACRIDONES AS INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2010-07-28 EP disclosed
EP-1458392-B1 ACRIDONES AS INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2009-09-02 EP disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 US disclosed
EP-1458392-A4 ACRIDONE INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2005-06-08 EP disclosed
EP-1458392-A2 ACRIDONE INHIBITORS OF IMPDH ENZYME Bristol-Myers Squibb Company (US) 2004-09-22 EP disclosed
US-20040053955-A1 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY 2004-03-18 US disclosed
WO-2003059269-A2 ACRIDONE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053955-A1 Acridone inhibitors of IMPDH enzyme IMPDH2, IMPDH1, XDH ALDH1A1 39/4885HSD17B10 83/4885GAA 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.